Today: 21 June 2026

CompoSecure stock jumps on $2.5 billion refinancing, GPGI ticker switch ahead

CompoSecure stock jumps on $2.5 billion refinancing, GPGI ticker switch ahead

CompoSecure shares rose about 8% Wednesday after the company announced a $900 million private placement of senior secured notes due 2033 with a 5.625% coupon and a $1.2 billion term loan. The company also confirmed its acquisition of Husky Technologies and will rebrand, trading as “GPGI” from Jan. 23. The Husky deal included $688.7 million in cash and nearly 55 million Class A shares.
14 January 2026
·
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next

Cogent Biosciences shares climbed about 8% Wednesday after the company set a 2026 timetable for U.S. filings of its lead drug, bezuclastinib. Cogent expects FDA acceptance of its first application by the end of February and aims for a possible commercial launch in the second half of 2026. The stock traded at $38.17 midday. The company began the year with about $900 million in cash.
14 January 2026
·
Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics stock jumps 11% as CEO flags broader appetite for obesity-drug deals

Viking Therapeutics shares surged about 11% to $34.06 by early afternoon Wednesday amid renewed speculation of a deal in obesity drugs. CEO Brian Lian said more companies are “circling around the space” at the J.P. Morgan healthcare conference. Viking reported Phase 2 trial data for VK2735 showing up to 14.7% weight loss after 13 weeks. No official deals have been announced.
14 January 2026
·
Lumentum stock slides 8% in afternoon trade as tech pulls back; Feb. 3 earnings ahead

Lumentum stock slides 8% in afternoon trade as tech pulls back; Feb. 3 earnings ahead

Lumentum Holdings shares fell 8.1% to $331.93 Wednesday, deepening losses for the Nasdaq-listed optical components maker. The stock swung from an intraday high of $363 to a low of $331.56. Other optics and data-center hardware stocks also declined, including Coherent, Ciena, Arista Networks, and Credo Technology. Lumentum will report fiscal Q2 earnings on Feb. 3 after the market closes.
14 January 2026
···
KLA stock slips despite fresh Wall Street upgrades — here’s what’s driving KLAC now

KLA stock slips despite fresh Wall Street upgrades — here’s what’s driving KLAC now

KLA shares fell 1.7% to $1,417.18 in early afternoon trading Wednesday, tracking a broader decline in chip stocks. The drop came despite new analyst upgrades and price target hikes from Bernstein SocGen, TD Cowen, and Stifel. Peers Applied Materials and Lam Research also slipped. Investors are awaiting KLA’s Jan. 29 earnings and details on 2026 spending plans for advanced chip manufacturing.
14 January 2026
·
SMCI stock slides again as Goldman’s ‘sell’ call puts Super Micro margins back under the microscope

SMCI stock slides again as Goldman’s ‘sell’ call puts Super Micro margins back under the microscope

Super Micro Computer shares fell 1.7% to $28.12 by early afternoon after Goldman Sachs initiated coverage with a “Sell” rating and a $26 price target, citing margin pressure and uncertain profitability. Analyst Katherine Murphy flagged that margins have halved to 9.5% and warned of further downside. Investors are awaiting February results for signs of margin stability. Competitors and rising costs are adding pressure.
14 January 2026
··
Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Edgewise Therapeutics shares rose 10.6% to $27.59 by midday Wednesday after the company set timelines for key clinical trial readouts in muscle and heart diseases. Top-line data for Becker muscular dystrophy is expected in Q4 2026, with a U.S. drug application planned for early 2027. Investors are watching for Phase 2 and Phase 1 heart program results in the first half of 2026. Trading volume reached about 1 million shares.
14 January 2026
··
Qualcomm stock falls again as “glass cloth” supply report rattles chip names ahead of earnings

Qualcomm stock falls again as “glass cloth” supply report rattles chip names ahead of earnings

Qualcomm shares fell 1.5% to $162.73 early Wednesday afternoon, extending a multi-day slide amid concerns over a shortage of high-end glass cloth used in advanced chip packaging. Trading volume reached about 3.4 million shares. Apple and Qualcomm are seeking new suppliers, but industry sources say more capacity may not arrive before late 2027. TSMC reports earnings early Thursday, with Qualcomm’s report due Feb. 4.
14 January 2026
····
Spotify stock slides after Bernstein slashes target to $650 as AI push hits valuation nerves

Spotify stock slides after Bernstein slashes target to $650 as AI push hits valuation nerves

Spotify shares fell 2.5% to $521.28 after Bernstein and Wells Fargo cut their price targets, citing risks tied to AI-driven products and new offerings. The stock has slid since Jan. 8 as investors await Feb. 10 earnings for clarity on 2026 margins and pricing. Founder Daniel Ek stepped down as CEO Jan. 1, replaced by co-CEOs Alex Norström and Gustav Söderström.
14 January 2026
···
CBA shares slide again — here’s what’s spooking Commonwealth Bank investors ahead of earnings

CBA shares slide again — here’s what’s spooking Commonwealth Bank investors ahead of earnings

Commonwealth Bank of Australia shares fell 1.3% to A$152.88 Wednesday, lagging the ASX 200’s 0.14% gain. Morgan Stanley flagged CBA’s 45% valuation premium as a risk for 2026 returns. CBA wage data showed a 0.8% quarterly rise and steady 4.3% unemployment. The Reserve Bank of Australia will announce its next policy decision on Feb. 3.
14 January 2026
··
Snowflake stock slides again after Barclays downgrade; traders eye next earnings date

Snowflake stock slides again after Barclays downgrade; traders eye next earnings date

Snowflake shares dropped 1.4% to $206.52 by midday Wednesday, extending losses after Barclays downgraded the stock and cut its price target to $250. The stock remains below its 200-day moving average after falling 5.1% Tuesday. Broader tech shares also declined, with the Invesco QQQ Trust down 1.6%. Trading volume in Snowflake was heavier than usual following the downgrade.
14 January 2026
····
StubHub (STUB) investors face Jan. 23 deadline as IPO class action targets cash-flow disclosures

StubHub (STUB) investors face Jan. 23 deadline as IPO class action targets cash-flow disclosures

StubHub shares traded at $13.34 midday Wednesday, down about 43% from their $23.50 IPO price. Two U.S. law firms notified investors they have until Jan. 23 to seek lead-plaintiff status in a securities class action tied to the September 2025 IPO. The suit alleges vendor-payment timing hurt free cash flow and made disclosures misleading. StubHub reported negative free cash flow of $4.6 million for the third quarter.
14 January 2026
··
1 … 853 854 855 856 857 … 2,088

Stock Market Today

  • Top 3 FTSE Shares for Beginner Investors to Buy in 2026
    June 21, 2026, 3:05 AM EDT. AstraZeneca, RELX, and another leading FTSE stock stand out as strong picks for beginner investors in 2026. AstraZeneca, a global pharmaceutical giant, boasts a 'best in class' drug pipeline with a raised price target of 16,500p by Bank of America, highlighting potential sales growth despite risks from clinical trial outcomes. RELX, an information analytics provider embedding AI into its platforms, is seen as a 'mis-priced AI beneficiary' with shares trading below historical multiples after a tough 2025. These companies offer durable moats and growth prospects, but investors should weigh optimisms against inherent risks like clinical failures and AI adoption speed.

Latest articles

Home Depot shares finish week up as investors weigh housing numbers

Home Depot shares finish week up as investors weigh housing numbers

21 June 2026
Home Depot jumped 2.1% to $334.28 in a shortened week as Wall Street rallied, but weak U.S. housing starts and upcoming May new-home-sales data keep pressure on the home-improvement outlook; the company reaffirmed 2026 sales and earnings targets despite volatile conditions and persistent housing affordability concerns.
Go toTop